Apel­lis grabs $60M to pay for a loom­ing PhI­II show­down with Alex­ion's Soliris

Back­ing up da­ta from small but promis­ing stud­ies for their ri­val ther­a­py to Soliris, Louisville-based Apel­lis has round­ed up a $60 mil­lion round to pay for a late-stage show­down with Alex­ion $ALXN.

Hav­ing tried and failed to pull off an IPO in chilly mar­ket wa­ters, this E round in­cludes some top ven­ture play­ers — who may be re­cal­cu­lat­ing the biotech’s shot at a re­peat ef­fort on the IPO front. Sec­toral As­set Man­age­ment led the round with Sofinno­va, Vi­vo Cap­i­tal, F-Prime Cap­i­tal Part­ners, cer­tain in­vest­ment funds ad­vised by Clough Cap­i­tal Part­ners, and ven­Bio Se­lect join­ing as new in­vestors. Ex­ist­ing in­vestors Morn­ing­side Ven­tures, Cor­morant As­set Man­age­ment, ven­Bio Glob­al Strate­gic Fund, and Ep­i­darex Cap­i­tal al­so par­tic­i­pat­ed in the fi­nanc­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.